Biomerica (BMRA)
Market Price (12/29/2025): $2.73 | Market Cap: $7.2 MilSector: Health Care | Industry: Life Sciences Tools & Services
Biomerica (BMRA)
Market Price (12/29/2025): $2.73Market Cap: $7.2 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -38% | Weak multi-year price returns2Y Excs Rtn is -118%, 3Y Excs Rtn is -172% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -4.9 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -100% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Advanced Diagnostics, Show more. | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -11%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -27%, Rev Chg QQuarterly Revenue Change % is -24% | |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 11% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -57%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -57% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -55% | ||
| High stock price volatilityVol 12M is 141% | ||
| Key risksBMRA key risks include [1] severe financial distress, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -38% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Advanced Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -118%, 3Y Excs Rtn is -172% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -4.9 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -100% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -11%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -27%, Rev Chg QQuarterly Revenue Change % is -24% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 11% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -57%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -57% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -55% |
| High stock price volatilityVol 12M is 141% |
| Key risksBMRA key risks include [1] severe financial distress, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
Stock Movement Drivers
Fundamental Drivers
The -3.9% change in BMRA stock from 9/28/2025 to 12/28/2025 was primarily driven by a -19.6% change in the company's Shares Outstanding (Mil).| 9282025 | 12282025 | Change | |
|---|---|---|---|
| Stock Price ($) | 2.81 | 2.70 | -3.91% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 5.31 | 4.88 | -8.04% |
| P/S Multiple | 1.17 | 1.46 | 24.93% |
| Shares Outstanding (Mil) | 2.21 | 2.64 | -19.57% |
| Cumulative Contribution | -7.59% |
Market Drivers
9/28/2025 to 12/28/2025| Return | Correlation | |
|---|---|---|
| BMRA | -3.9% | |
| Market (SPY) | 4.3% | 27.8% |
| Sector (XLV) | 15.2% | 6.6% |
Fundamental Drivers
The -14.3% change in BMRA stock from 6/29/2025 to 12/28/2025 was primarily driven by a -14.0% change in the company's Total Revenues ($ Mil).| 6292025 | 12282025 | Change | |
|---|---|---|---|
| Stock Price ($) | 3.15 | 2.70 | -14.29% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 5.68 | 4.88 | -13.98% |
| P/S Multiple | 1.33 | 1.46 | 9.64% |
| Shares Outstanding (Mil) | 2.40 | 2.64 | -10.02% |
| Cumulative Contribution | -15.15% |
Market Drivers
6/29/2025 to 12/28/2025| Return | Correlation | |
|---|---|---|
| BMRA | -14.3% | |
| Market (SPY) | 12.6% | 15.2% |
| Sector (XLV) | 17.0% | 4.3% |
Fundamental Drivers
The 7.0% change in BMRA stock from 12/28/2024 to 12/28/2025 was primarily driven by a 51.4% change in the company's P/S Multiple.| 12282024 | 12282025 | Change | |
|---|---|---|---|
| Stock Price ($) | 2.52 | 2.70 | 7.01% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 5.51 | 4.88 | -11.31% |
| P/S Multiple | 0.96 | 1.46 | 51.38% |
| Shares Outstanding (Mil) | 2.10 | 2.64 | -25.46% |
| Cumulative Contribution | 0.07% |
Market Drivers
12/28/2024 to 12/28/2025| Return | Correlation | |
|---|---|---|
| BMRA | 7.0% | |
| Market (SPY) | 17.0% | 19.6% |
| Sector (XLV) | 13.8% | 10.0% |
Fundamental Drivers
The -89.8% change in BMRA stock from 12/29/2022 to 12/28/2025 was primarily driven by a -74.6% change in the company's Total Revenues ($ Mil).| 12292022 | 12282025 | Change | |
|---|---|---|---|
| Stock Price ($) | 26.40 | 2.70 | -89.77% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 19.25 | 4.88 | -74.62% |
| P/S Multiple | 2.25 | 1.46 | -35.06% |
| Shares Outstanding (Mil) | 1.64 | 2.64 | -61.14% |
| Cumulative Contribution | -93.60% |
Market Drivers
12/29/2023 to 12/28/2025| Return | Correlation | |
|---|---|---|
| BMRA | -73.0% | |
| Market (SPY) | 48.4% | 17.5% |
| Sector (XLV) | 17.8% | 11.6% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| BMRA Return | 65% | -22% | -14% | -63% | -76% | 10% | -89% |
| Peers Return | 16% | 38% | -12% | 21% | 26% | 16% | 150% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 18% | 114% |
Monthly Win Rates [3] | |||||||
| BMRA Win Rate | 50% | 50% | 50% | 25% | 33% | 42% | |
| Peers Win Rate | 52% | 65% | 42% | 68% | 57% | 52% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| BMRA Max Drawdown | -22% | -32% | -33% | -79% | -79% | -9% | |
| Peers Max Drawdown | -34% | -5% | -26% | -7% | -9% | -23% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/26/2025 (YTD)
How Low Can It Go
| Event | BMRA | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -91.1% | -25.4% |
| % Gain to Breakeven | 1026.8% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -70.6% | -33.9% |
| % Gain to Breakeven | 239.7% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
| 2018 Correction | ||
| % Loss | -67.9% | -19.8% |
| % Gain to Breakeven | 211.8% | 24.7% |
| Time to Breakeven | 443 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -78.4% | -56.8% |
| % Gain to Breakeven | 362.9% | 131.3% |
| Time to Breakeven | 2,762 days | 1,480 days |
Compare to HPQ, HPE, IBM, CSCO, AAPL
In The Past
Biomerica's stock fell -91.1% during the 2022 Inflation Shock from a high on 2/10/2021. A -91.1% loss requires a 1026.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
AI Analysis | Feedback
- A specialized diagnostics company, similar to a smaller Abbott Laboratories.
- Like Exact Sciences, but with a focus on a broader range of digestive health and gastrointestinal diagnostic tests.
AI Analysis | Feedback
- PMA-IBS Diagnostic Test: A blood-based test designed to aid in the diagnosis of Irritable Bowel Syndrome (IBS).
- EZ DETECT Colorectal Disease Screening Test: A rapid, in-home test for detecting occult blood in stool, indicating potential colorectal disease.
- Gastrointestinal (GI) Diagnostic Tests: A range of *in-vitro* diagnostic products for identifying and monitoring various GI disorders, including Inflammatory Bowel Disease (IBD) and *H. pylori* infections.
- Food Intolerance Tests: Diagnostic panels to identify sensitivities to various food antigens.
AI Analysis | Feedback
Biomerica (BMRA) primarily sells its diagnostic and therapeutic products to other companies and healthcare institutions, rather than directly to individuals. The company's business model is largely B2B (business-to-business).
According to Biomerica's SEC filings (e.g., their annual report on Form 10-K), no single customer accounts for more than 10% of its annual sales. This means that Biomerica does not have individually identifiable "major customers" that are publicly disclosed and account for a significant portion of its revenue. Instead, Biomerica serves a diverse base of customers through various channels:
- International Distributors: Biomerica sells its products to a network of distributors in over 70 countries worldwide. These distributors then resell Biomerica's products to local hospitals, clinics, and laboratories in their respective regions. The specific names of these distributors are not publicly disclosed as major customers.
- U.S. Healthcare Providers: In the United States, Biomerica sells products directly to various healthcare entities including hospitals, clinics, physician offices, and dietitians. For instance, their InFoods® IBS product is made available through physicians and dietitians who order the diagnostic test for their patients.
- Clinical Laboratories: Biomerica's diagnostic tests are also utilized by clinical reference laboratories. These laboratories purchase the tests and associated equipment from Biomerica to process patient samples and provide diagnostic services to healthcare providers.
AI Analysis | Feedback
nullAI Analysis | Feedback
Zackary S. Irani, Chief Executive Officer & Chairman of the Board
Mr. Irani has served as Biomerica's Chairman of the Board and Chief Executive Officer since April 29, 1997, and has been an employee of the company since 1986, initially serving as Vice-President of Business Development. During fiscal years 2008 and 2009, he also held the position of Chairman of the Board for Lancer Orthodontics, Inc., and was its Chief Executive Officer from April 1997 to April 2004.
Gary Lu, Chief Financial Officer
Mr. Lu was appointed as Biomerica's Chief Financial Officer on March 1, 2023. With over two decades of financial leadership, he previously served as Controller and Vice President of Finance at Happy Money from September 2019 to February 2023, where he contributed to scaling the company from $15 million to over $200 million in revenue and helped raise more than $200 million in capital. His experience also includes roles as Controller and Vice President of Finance at Verb Technology Company Inc., Vice President Southwest Corporate Controller at FirstService Residential Management, Inc., Corporate Controller and Head of Finance at Hoag Orthopedic Institute, LLC, and various finance roles at Broadcom Inc. Mr. Lu began his career as an Assurance Manager at Ernst & Young, LLP, and is a Certified Public Accountant.
Allen C. Barbieri, Executive Vice Chairman
Mr. Barbieri has been a Director of Biomerica since October 1999 and has served as Executive Director and Vice Chairman since August 2020. He is currently a private investor. From January 2010 to March 2018, Mr. Barbieri was the Chief Executive Officer of Biosynthetic Technologies, a privately held specialty chemicals company with BP and Monsanto as primary investors. He successfully raised $60 million in venture capital funding and oversaw the sale of Biosynthetic Technologies to a large international chemicals private equity fund. Prior to that, from April 2004 to September 2009, he served as Chief Executive Officer of Lancer Orthodontics, Inc. His past experience also includes serving as President and Chief Financial Officer of BUY.COM from 1998 to 1999, and President and Chief Executive Officer of Pacific National Bank from 1994 to 1999, which was subsequently sold to US Bank.
Scott Madel, Chief Commercial Officer
Mr. Madel was appointed as Biomerica's Chief Commercial Officer on June 26, 2025, bringing over 20 years of experience in the healthcare and diagnostics sectors. Most recently, he served as President of Boston Heart Diagnostics, where he led a successful organizational turnaround. He has also held CEO positions at BioHealth Diagnostics and Genova Diagnostics Europe, where he helped grow Genova to over $100 million in annual revenue. His early career involved frontline field sales roles at Novartis Pharmaceuticals and Merck.
AI Analysis | Feedback
The key risks for the public company Biomerica (BMRA) are primarily related to its financial health, exacerbated by trade challenges and the inherent volatility and competitive pressures within its sector.
- Financial Health and Sustainability: Biomerica faces significant financial challenges, including a continuous decline in revenue growth and persistently negative profitability margins across gross, operating, and net income. The company has experienced negative cash flows, indicating liquidity challenges that could hinder its ability to fund operations and growth initiatives. Furthermore, an Altman Z-Score of -8.53 places the company in a distress zone, suggesting a potential risk of bankruptcy within the next two years. A recent 1-for-8 reverse stock split was implemented to increase its stock price to comply with Nasdaq listing requirements, which can signal financial instability and a lack of investor confidence.
- Trade Challenges and Supply Chain Disruptions: The company is exposed to business risks stemming from tariffs and evolving trade dynamics. These factors have resulted in extended lead times for products and rescheduled international shipments, directly impacting revenue recognition timing and overall operational efficiency. The ongoing uncertainty in trade policies could continue to disrupt Biomerica's supply chain and revenue streams, requiring constant strategic adjustments.
- Sector-Specific Risks and Market Volatility: Operating within the healthcare sector, Biomerica is susceptible to rapid regulatory changes and intense competitive pressures that can affect its market position. Additionally, the company's stock exhibits high volatility, with a beta of 1.16, indicating its sensitivity to broader market movements and potentially higher risk for investors.
AI Analysis | Feedback
The emergence and increasing adoption of comprehensive gut microbiome and metabolomics analysis platforms, offering personalized insights and recommendations for gut health, including conditions like IBS and food sensitivities, represent a clear emerging threat to Biomerica. These platforms often leverage advanced sequencing technologies and artificial intelligence to provide a more holistic understanding of an individual's gut ecosystem, potentially offering more actionable and personalized solutions compared to Biomerica's more traditional, targeted diagnostic tests for specific markers or intolerances. Companies in this space are actively gaining market share and investment, driving a shift in how consumers and healthcare providers approach gut health management, which could diminish the perceived value or comprehensiveness of Biomerica's current product offerings in its core gastroenterology diagnostics market.
AI Analysis | Feedback
Biomerica (BMRA) operates in several diagnostic markets. The addressable markets for its main products and services include:
- Irritable Bowel Syndrome (IBS) Diagnostics: The global irritable bowel syndrome diagnostics market was estimated at approximately $5.5 billion in 2025, with a projected compound annual growth rate (CAGR) of about 12.5% through 2033. Another estimate placed the global market at USD 2.47 billion in 2020, expected to reach USD 3.88 billion by 2028, growing at a CAGR of 5.80%. North America and Europe are anticipated to be leading regions in this market.
- Colorectal Cancer (CRC) Diagnostics: The global colorectal cancer diagnostics market was estimated at USD 14.5 billion in 2024 and is projected to reach USD 26.6 billion by 2034, with a CAGR of 6.4%. Another report estimated the global market size at USD 4.14 billion in 2024, expected to grow to USD 7.89 billion by 2032, at a CAGR of 8.40%. The North American colorectal cancer diagnostics market was valued at USD 4.7 billion in 2024, holding a 35.2% share of the global market. The global market for colorectal cancer screening and diagnostic testing services is estimated to increase from $40.0 billion in 2024 to $46.1 billion by 2029, at a CAGR of 2.9%.
- Helicobacter pylori (H. pylori) Diagnostics: The global Helicobacter pylori diagnostics market size was valued at USD 698.44 million in 2024 and is projected to reach USD 966.19 million by 2030, growing at a CAGR of 5.87%. Another source indicates the global H. pylori testing market was valued at USD 517.8 million in 2024 and is expected to reach USD 1 billion by 2034, at a CAGR of 7.1%. North America held a significant share, with the U.S. H. pylori testing market reaching USD 165.6 million in 2024.
For Biomerica's other product segments, such as Diabetes and Chronic Disease Monitoring, Women's Health Diagnostics, and Contract Development and Manufacturing Organization (CDMO) services, specific addressable market sizes were not readily available in the provided search results.
AI Analysis | Feedback
Biomerica (BMRA) is expected to drive future revenue growth over the next 2-3 years through several key initiatives: * Expansion of EZ Detect™ and Aware® Products in the MENA Region: Biomerica is strategically focused on expanding its EZ Detect™ colorectal screening tests and Aware® breast self-exam products, particularly in the Middle East and North Africa (MENA) region. This is evidenced by strong demand and a multi-year exclusive distribution agreement secured in the UAE, with goals to integrate these tests into national health protocols. * Commercialization and Adoption of inFoods® IBS Diagnostic Test: The company anticipates significant revenue growth from its inFoods® IBS diagnostic test. Key developments supporting this include a pilot program with a large 1,100-physician group progressing ahead of schedule, the introduction of a new patient self-collection system, and the issuance of a Proprietary Laboratory Analysis (PLA) code by the American Medical Association CPT Editorial Panel for the test to aid reimbursement. Additionally, a marketing services agreement with Henry Schein for the inFoods® IBS test in the U.S. is expected to broaden its market reach. * Growth in H. pylori Antigen Sales in the U.S. with Hp Detect™: Following the U.S. Food and Drug Administration (FDA) 510(k) clearance for its Hp Detect™ Stool Antigen ELISA test, Biomerica expects meaningful revenue opportunities from H. pylori antigen sales in the United States. * Expansion of Contract Development and Manufacturing Organization (CDMO) Services: Biomerica is expanding its CDMO services to meet increasing market demand, providing end-to-end support from concept through commercial manufacturing for diagnostic innovators. This area is noted as a growing contributor to revenue and a significant growth opportunity.AI Analysis | Feedback
Share Issuance
- Biomerica implemented a 1-for-8 reverse stock split, effective April 21, 2025, to regain compliance with Nasdaq's minimum bid price requirement.
- This reverse split reduced the number of outstanding shares from approximately 20.37 million to about 2.55 million.
Inbound Investments
- While institutional investors have both increased and decreased their positions, no specific large, strategic inbound investments by third-parties (e.g., private equity firms or strategic partners) were identified within the given timeframe.
Capital Expenditures
- Biomerica reduced its operating expenses by over $1.3 million in fiscal year 2025.
- Research and development (R&D) expenses decreased from $1.5 million in the prior year to $1.0 million in fiscal 2025, reflecting a focus on cost discipline.
- The company continues to prioritize operational efficiency and selectively invest in core diagnostic programs to support long-term profitability.
Latest Trefis Analyses
| Title | Topic | |
|---|---|---|
| DASHBOARDS | ||
| Biomerica Earnings Notes | ||
| With Biomerica Stock Sliding, Have You Assessed The Risk? | Return |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to BMRA. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 21.4% | 21.4% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -7.4% | -7.4% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 18.0% | 18.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.9% | 3.9% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 12.2% | 12.2% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Biomerica
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 51.32 |
| Mkt Cap | 158.8 |
| Rev LTM | 56,496 |
| Op Inc LTM | 7,584 |
| FCF LTM | 7,327 |
| FCF 3Y Avg | 7,366 |
| CFO LTM | 8,590 |
| CFO 3Y Avg | 8,697 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.2% |
| Rev Chg 3Y Avg | 2.2% |
| Rev Chg Q | 8.3% |
| QoQ Delta Rev Chg LTM | 2.0% |
| Op Mgn LTM | 12.1% |
| Op Mgn 3Y Avg | 11.9% |
| QoQ Delta Op Mgn LTM | -0.1% |
| CFO/Rev LTM | 14.6% |
| CFO/Rev 3Y Avg | 17.1% |
| FCF/Rev LTM | 11.6% |
| FCF/Rev 3Y Avg | 12.1% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Development, manufacture, marketing, and sale of diagnostic products | 5 | 5 | 19 | 7 | 7 |
| Total | 5 | 5 | 19 | 7 | 7 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Development, manufacture, marketing, and sale of diagnostic products | -6 | ||||
| Total | -6 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Development, manufacture, marketing, and sale of diagnostic products | -6 | ||||
| Total | -6 |
Price Behavior
| Market Price | $2.70 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 02/23/2007 | |
| Distance from 52W High | -67.2% | |
| 50 Days | 200 Days | |
| DMA Price | $2.55 | $3.25 |
| DMA Trend | down | down |
| Distance from DMA | 5.8% | -17.0% |
| 3M | 1YR | |
| Volatility | 53.9% | 141.0% |
| Downside Capture | 143.66 | 204.00 |
| Upside Capture | 95.50 | 180.00 |
| Correlation (SPY) | 28.1% | 19.8% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.27 | 1.21 | 1.20 | 1.10 | 1.41 | 1.00 |
| Up Beta | 1.79 | 1.89 | 1.41 | -0.52 | 0.82 | 0.28 |
| Down Beta | -2.31 | 1.39 | 1.38 | 0.60 | 1.99 | 1.43 |
| Up Capture | 17% | 10% | 5% | 108% | 182% | 33% |
| Bmk +ve Days | 12 | 25 | 38 | 73 | 141 | 426 |
| Stock +ve Days | 7 | 16 | 27 | 55 | 106 | 329 |
| Down Capture | 243% | 158% | 183% | 220% | 140% | 110% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 12 | 24 | 33 | 64 | 136 | 393 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Comparison of BMRA With Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| BMRA | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 21.0% | 15.1% | 17.8% | 72.1% | 8.6% | 4.4% | -8.2% |
| Annualized Volatility | 140.7% | 17.2% | 19.4% | 19.3% | 15.2% | 17.0% | 35.0% |
| Sharpe Ratio | 0.65 | 0.65 | 0.72 | 2.70 | 0.34 | 0.09 | -0.08 |
| Correlation With Other Assets | 10.2% | 19.6% | 4.4% | 10.0% | 20.7% | 6.0% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Comparison of BMRA With Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| BMRA | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -43.0% | 8.4% | 14.7% | 18.7% | 11.5% | 4.6% | 30.8% |
| Annualized Volatility | 100.8% | 14.5% | 17.1% | 15.5% | 18.7% | 18.9% | 48.6% |
| Sharpe Ratio | -0.14 | 0.40 | 0.70 | 0.97 | 0.50 | 0.16 | 0.57 |
| Correlation With Other Assets | 6.4% | 13.8% | 3.1% | 4.5% | 9.4% | 7.3% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Comparison of BMRA With Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| BMRA | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -21.5% | 9.9% | 14.8% | 15.3% | 7.0% | 5.3% | 69.2% |
| Annualized Volatility | 143.6% | 16.6% | 18.0% | 14.7% | 17.6% | 20.8% | 55.8% |
| Sharpe Ratio | 0.23 | 0.49 | 0.71 | 0.86 | 0.32 | 0.22 | 0.90 |
| Correlation With Other Assets | -1.1% | 0.8% | -2.3% | -0.5% | -6.5% | 5.5% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 12/16/2021 | -1.5% | 7.6% | 8.1% |
| SUMMARY STATS | |||
| # Positive | 0 | 1 | 1 |
| # Negative | 1 | 0 | 0 |
| Median Positive | 7.6% | 8.1% | |
| Median Negative | -1.5% | ||
| Max Positive | 7.6% | 8.1% | |
| Max Negative | -1.5% | ||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 8312025 | 10142025 | 10-Q 8/31/2025 |
| 5312025 | 8292025 | 10-K 5/31/2025 |
| 2282025 | 4142025 | 10-Q 2/28/2025 |
| 11302024 | 1142025 | 10-Q 11/30/2024 |
| 8312024 | 10152024 | 10-Q 8/31/2024 |
| 5312024 | 8282024 | 10-K 5/31/2024 |
| 2292024 | 4122024 | 10-Q 2/29/2024 |
| 11302023 | 1162024 | 10-Q 11/30/2023 |
| 8312023 | 10122023 | 10-Q 8/31/2023 |
| 5312023 | 8252023 | 10-K 5/31/2023 |
| 2282023 | 4142023 | 10-Q 2/28/2023 |
| 11302022 | 1132023 | 10-Q 11/30/2022 |
| 8312022 | 10132022 | 10-Q 8/31/2022 |
| 5312022 | 8292022 | 10-K 5/31/2022 |
| 2282022 | 4142022 | 10-Q 2/28/2022 |
| 11302021 | 1122022 | 10-Q 11/30/2021 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.